{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T05:09:17Z","timestamp":1737522557469,"version":"3.33.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1038\/sj.bmt.1705867","type":"journal-article","created":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T10:34:57Z","timestamp":1191234897000},"page":"1097-1100","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The evolving background for high-dose treatment for myeloma"],"prefix":"10.1038","volume":"40","author":[{"given":"B","family":"Sirohi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Powles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J L","family":"Harousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K C","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,10,1]]},"reference":[{"key":"BF1705867_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"355","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. Prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 355: 91\u201397.","journal-title":"New Engl J Med"},{"key":"BF1705867_CR2","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495\u20132502.","journal-title":"N Engl J Med"},{"key":"BF1705867_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMoa065464","volume":"356","author":"B Bruno","year":"2007","unstructured":"Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110\u20131120.","journal-title":"N Engl J Med"},{"key":"BF1705867_CR4","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","volume":"102","author":"DG Maloney","year":"2003","unstructured":"Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447\u20133454.","journal-title":"Blood"},{"key":"BF1705867_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/sj.bmt.1705000","volume":"36","author":"B Sirohi","year":"2005","unstructured":"Sirohi B, Powles R, Mehta J, Rudin C, Kulkarni S, Horton C et al. An elective single autograft with high-dose melphalan: single-center study of 451 patients. Bone Marrow Transplant 2005; 36: 19\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705867_CR6","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1365-2141.1987.tb06890.x","volume":"66","author":"PJ Selby","year":"1987","unstructured":"Selby PJ, McElwain TJ, Nandi AC, Perren TJ, Powles RL, Tillyer CR et al. Multiple myeloma treated with high-dose intravenous melphalan. Br J Haematol 1987; 66: 52\u201355.","journal-title":"Br J Haematol"},{"key":"BF1705867_CR7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL . High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1983; 2: 822\u2013824.","journal-title":"Lancet"},{"key":"BF1705867_CR8","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1182\/blood.V67.5.1298.1298","volume":"67","author":"B Barlogie","year":"1986","unstructured":"Barlogie B, Hall R, Zander A, Dicke K, Alexanian R . High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298\u20131301.","journal-title":"Blood"},{"key":"BF1705867_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","volume":"325","author":"G Gahrton","year":"1991","unstructured":"Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M et al. Allogeneic bone marrow transplantation in multiple myeloma. European group for bone marrow transplantation. N Engl J Med 1991; 325: 1267\u20131273.","journal-title":"N Engl J Med"},{"key":"BF1705867_CR10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.bmt.1700917","volume":"20","author":"R Powles","year":"1997","unstructured":"Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J et al. Outcome assessment of a population based group of 195 patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997; 20: 435\u2013443.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705867_CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55\u201365.","journal-title":"Blood"},{"key":"BF1705867_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0041-1345(98)01603-0","volume":"31","author":"R Storb","year":"1999","unstructured":"Storb R, Yu C, Sandmaier B, McSweeney P, Georges G, Nash R et al. Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplant Proc 1999; 31: 677\u2013678.","journal-title":"Transplant Proc"},{"key":"BF1705867_CR13","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875\u20131883.","journal-title":"N Engl J Med"},{"key":"BF1705867_CR14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.37464\/2006.234.1921","volume":"23","author":"W Johnson","year":"2006","unstructured":"Johnson W, Kerridge I, Milton C, Carr D, Enno A, Bray L et al. Hospital in the home (HITH) care following autologous stem cell transplantation for lymphoma and multiple myeloma. Aust J Adv Nurs 2006; 23: 34\u201339.","journal-title":"Aust J Adv Nurs"},{"key":"BF1705867_CR15","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825\u2013831.","journal-title":"Lancet"},{"key":"BF1705867_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.bbmt.2006.09.010","volume":"13","author":"J Koreth","year":"2007","unstructured":"Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007; 13: 183\u2013196.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1705867_CR17","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/annonc\/mdm180","volume":"18","author":"B Sirohi","year":"2007","unstructured":"Sirohi B, Powles R, Lawrence D, Treleaven J, Kulkarni S, Leary A et al. An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-{alpha}2b in patients with multiple myeloma maintained on a steady dose of interferon-{alpha}2b. Ann Oncol 2007; 18: 1388\u20131394.","journal-title":"Ann Oncol"},{"key":"BF1705867_CR18","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","volume":"108","author":"M Attal","year":"2006","unstructured":"Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289\u20133294.","journal-title":"Blood"},{"key":"BF1705867_CR19","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/sj.bmt.1701634","volume":"23","author":"S Kulkarni","year":"1999","unstructured":"Kulkarni S, Powles RL, Treleaven JG, Singhal S, Saso R, Horton C et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant 1999; 23: 675\u2013680.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705867_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BGM Durie","year":"1975","unstructured":"Durie BGM, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842\u2013854.","journal-title":"Cancer"},{"key":"BF1705867_CR21","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412\u20133420.","journal-title":"J Clin Oncol"},{"key":"BF1705867_CR22","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1046\/j.1365-2141.1999.01744.x","volume":"107","author":"B Sirohi","year":"1999","unstructured":"Sirohi B, Powles R, Mehta J, Raje N, Kulkarni S, Ramiah V et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system. Br J Haematol 1999; 107: 656\u2013666.","journal-title":"Br J Haematol"},{"key":"BF1705867_CR23","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0140-6736(89)91548-1","volume":"2","author":"ME Gore","year":"1989","unstructured":"Gore ME, Selby PJ, Viner C, Clark PI, Meldrum M, Millar B et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879\u2013881.","journal-title":"Lancet"},{"key":"BF1705867_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, Apperley J, Bj\u00f6rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European group for blood and marrow transplant. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BF1705867_CR25","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705867","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705867.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T09:23:25Z","timestamp":1737451405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["BF1705867"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705867","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2007,10,1]]},"assertion":[{"value":"29 August 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}